[go: up one dir, main page]

CO6751288A2 - Composición antigénica de micobacteria - Google Patents

Composición antigénica de micobacteria

Info

Publication number
CO6751288A2
CO6751288A2 CO13146307A CO13146307A CO6751288A2 CO 6751288 A2 CO6751288 A2 CO 6751288A2 CO 13146307 A CO13146307 A CO 13146307A CO 13146307 A CO13146307 A CO 13146307A CO 6751288 A2 CO6751288 A2 CO 6751288A2
Authority
CO
Colombia
Prior art keywords
antigenic composition
mycobacterial antigenic
composition
mycobacterial
less
Prior art date
Application number
CO13146307A
Other languages
English (en)
Inventor
Stephane Andre Godart
Amina Laanan
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6751288A2 publication Critical patent/CO6751288A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

(Se proporcionan composiciones inmunogénicas que comprenden un antígeno relacionado con M72, en donde la conductividad de la composición es de 13 mS/cm o menor, o la concentración de sales de la composición es de 130 mM o menor, y su uso en medicina.
CO13146307A 2010-12-14 2013-06-19 Composición antigénica de micobacteria CO6751288A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
CO6751288A2 true CO6751288A2 (es) 2013-09-16

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
CO13146289A CO6751287A2 (es) 2010-12-14 2013-06-19 Composición antigénetica de micobacteria
CO13146307A CO6751288A2 (es) 2010-12-14 2013-06-19 Composición antigénica de micobacteria

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO13146289A CO6751287A2 (es) 2010-12-14 2013-06-19 Composición antigénetica de micobacteria

Country Status (33)

Country Link
US (5) US9730992B2 (es)
EP (4) EP2651437B1 (es)
JP (2) JP5951634B2 (es)
KR (3) KR20140029376A (es)
CN (4) CN106822882A (es)
AR (1) AR084285A1 (es)
AU (2) AU2011343367B2 (es)
BR (2) BR112013014599A2 (es)
CA (2) CA2819297A1 (es)
CO (2) CO6751287A2 (es)
CY (1) CY1122187T1 (es)
DK (3) DK3023106T3 (es)
EA (2) EA027920B1 (es)
ES (3) ES2574403T3 (es)
HR (3) HRP20160362T1 (es)
HU (3) HUE028452T2 (es)
IL (2) IL226448A (es)
LT (1) LT3023106T (es)
ME (1) ME02380B (es)
MX (2) MX344280B (es)
MY (1) MY161412A (es)
PH (2) PH12013501204A1 (es)
PL (3) PL2651436T3 (es)
PT (2) PT2651436E (es)
RS (1) RS54687B1 (es)
SG (2) SG190937A1 (es)
SI (3) SI2651437T1 (es)
SM (1) SMT201600118B (es)
TW (1) TW201305192A (es)
UA (2) UA110118C2 (es)
UY (1) UY33802A (es)
WO (2) WO2012080369A1 (es)
ZA (2) ZA201304015B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
PH12013501204A1 (en) 2010-12-14 2013-07-29 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
HUE032409T2 (en) * 2011-01-04 2017-09-28 Archivel Farma Sl Liposome preparation for treating or preventing tuberculosis
DK2802345T3 (en) 2012-01-12 2018-04-30 Archivel Farma Sl MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
DK4219687T3 (da) 2014-04-23 2024-10-28 Juno Therapeutics Inc Fremgangsmåder til isolering, dyrkning og genmanipulering af immuncellepopulationer til adoptiv terapi
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
AU2019313502A1 (en) 2018-07-31 2021-01-28 Glaxosmithkline Biologicals Sa Antigen purification method
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3092525A1 (en) 2019-09-09 2021-03-09 Glaxosmithkline Biologicals S.A. Immunotherapeutic compositions
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021224205A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20240026407A1 (en) 2020-12-09 2024-01-25 Glaxosmithkline Biologicals Sa Modification of saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69636046T2 (de) 1995-09-01 2006-11-23 CORIXA CORP., Wilmington Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
ATE530671T1 (de) 1995-09-01 2011-11-15 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
NZ500028A (en) * 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1068329A2 (en) * 1998-04-07 2001-01-17 Corixa Corporation FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES
AU746163B2 (en) * 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT1946769E (pt) 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CL2008001491A1 (es) * 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
KR100955470B1 (ko) 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
WO2009111874A1 (en) 2008-03-11 2009-09-17 The Royal Institution For The Advancement Of Learning/ Mcgiil University Low-temperature wafer level processing for mems devices
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
PH12013501204A1 (en) * 2010-12-14 2013-07-29 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
CA2819298A1 (en) 2012-06-21
CN103260642A (zh) 2013-08-21
EP3023106A1 (en) 2016-05-25
CO6751287A2 (es) 2013-09-16
ES2748651T3 (es) 2020-03-17
CA2819297A1 (en) 2012-06-21
ZA201304014B (en) 2017-04-26
PH12013501204A1 (en) 2013-07-29
AU2011343367A1 (en) 2013-07-11
KR20130124525A (ko) 2013-11-14
PL3023106T3 (pl) 2019-12-31
BR112013014598A2 (pt) 2017-09-19
UA110118C2 (uk) 2015-11-25
KR20140029376A (ko) 2014-03-10
CN103260642B (zh) 2018-03-16
JP5951633B2 (ja) 2016-07-13
AU2011343367B2 (en) 2015-05-21
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
KR20190022897A (ko) 2019-03-06
IL226448A (en) 2017-09-28
SG190937A1 (en) 2013-07-31
AU2011343368A1 (en) 2013-07-11
JP5951634B2 (ja) 2016-07-13
EP2651437B1 (en) 2016-02-10
KR101951894B1 (ko) 2019-02-26
SG190731A1 (en) 2013-07-31
ZA201304015B (en) 2018-12-19
BR112013014599A2 (pt) 2016-09-27
EP3023106B1 (en) 2019-07-31
IL226448A0 (en) 2013-07-31
WO2012080370A1 (en) 2012-06-21
US9730992B2 (en) 2017-08-15
IL226450A0 (en) 2013-07-31
PT2651436E (pt) 2016-06-08
LT3023106T (lt) 2019-10-25
WO2012080369A1 (en) 2012-06-21
EP2651436A1 (en) 2013-10-23
MY161412A (en) 2017-04-14
HUE027932T2 (en) 2016-11-28
DK3023106T3 (da) 2019-09-30
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
UA110806C2 (uk) 2016-02-25
ES2567190T3 (es) 2016-04-20
PH12013501203A1 (en) 2013-07-29
CY1122187T1 (el) 2020-11-25
SI2651437T1 (sl) 2016-05-31
PT3023106T (pt) 2019-11-04
MX344280B (es) 2016-12-09
MX344706B (es) 2017-01-03
EA027920B1 (ru) 2017-09-29
US20190183998A1 (en) 2019-06-20
AU2011343368B2 (en) 2015-08-20
EP2651436B1 (en) 2016-03-30
EA201390631A1 (ru) 2014-11-28
TW201305192A (zh) 2013-02-01
HRP20160606T1 (hr) 2016-07-01
DK2651436T3 (da) 2016-06-20
SI2651436T1 (sl) 2016-07-29
PL2651437T3 (pl) 2016-07-29
RS54687B1 (en) 2016-08-31
PL2651436T3 (pl) 2016-10-31
AU2011343368C1 (en) 2015-12-24
CN103249431B (zh) 2016-11-02
SI3023106T1 (sl) 2019-11-29
EP2651437A1 (en) 2013-10-23
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
UY33802A (es) 2012-07-31
EP3593813A1 (en) 2020-01-15
SMT201600118B (it) 2016-07-01
US20160220656A1 (en) 2016-08-04
MX2013006819A (es) 2013-08-26
DK2651437T3 (en) 2016-05-02
CN106822883A (zh) 2017-06-13
US9352030B2 (en) 2016-05-31
HRP20191843T1 (hr) 2019-12-27
ES2574403T3 (es) 2016-06-17
EA201390630A1 (ru) 2013-12-30
EA027504B1 (ru) 2017-08-31
US20180071378A1 (en) 2018-03-15
MX2013006818A (es) 2013-08-26
US20130280289A1 (en) 2013-10-24
JP2014505036A (ja) 2014-02-27
HUE028452T2 (en) 2016-12-28
CN103249431A (zh) 2013-08-14
US20130287809A1 (en) 2013-10-31
JP2013545783A (ja) 2013-12-26

Similar Documents

Publication Publication Date Title
CO6751288A2 (es) Composición antigénica de micobacteria
CR20140388A (es) Compuestos terapeuticamente activos y sus métodos de uso
EA201290199A1 (ru) Способы и композиции для получения сквалена с применением дрожжей
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
BR112015000520A2 (pt) agente de espessamento estável com lipase
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
BR112016005509A8 (pt) método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
BR112014013327A2 (pt) composições para cuidado oral
CL2011000621A1 (es) Agente que contiene por lo menos un acido acilciclohexanodionacarboxilico y/o sus sales en combinacion con por lo menos un ester de acido acilciclohexanodionacarboxilico y su uso para mejorar el desarrollo de gramineas.
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
BR112015020053A2 (pt) composições para cuidado oral
AR088908A1 (es) Vacuna
CO6690780A2 (es) Formulaciones para el factor estimulante de colonias de granulocitos bovino y variantes de las mismas
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico
AR086962A1 (es) Composiciones de cuidado oral
CY1117640T1 (el) Αντιγονικη συνθεση μυκοβακτηριου